会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明授权
    • Closed loop drug delivery system and remote management thereof
    • 闭环药物输送系统及其远程管理
    • US06453195B1
    • 2002-09-17
    • US09811685
    • 2001-03-19
    • David L. Thompson
    • David L. Thompson
    • A61N1362
    • A61N1/30A61N1/3956
    • A transdermal drug delivery device in communication with at least one IMD is externally mounted to deliver pain analgesics and/or threshold reduction medications prior to or contemporaneous with a shock associated with a pacer, a defibrillator and similar therapy device. The drug delivery device includes an attachable strip with a storage for medications and is epidermally mounted. The medications are released into the bloodstream in response to an indication that the IMD is about to deliver a shock. The drug delivery device is adapted for use with various drugs. Further, the delivery of drugs could be controlled by the patient to provide a semi-automatic use and/or to terminate delay shock. The transdermal drug delivery device and the IMD include system status indicators to provide real-time operational data of the drug delivery device and the IMD individually and in combination. The drug delivery device is also implemented with a CHF monitor to treat CHF patients.
    • 与至少一个IMD通信的透皮药物递送装置被外部安装以在与起搏器,除颤器和类似治疗装置相关的冲击之前或同时发生疼痛镇痛药和/或阈值减少药物。 药物递送装置包括具有用于药物的储存器的可附接条带并且被表皮地安装。 药物被释放到血液中,以反映IMD即将发生冲击的迹象。 药物输送装置适用于各种药物。 此外,药物的输送可以由患者控制以提供半自动使用和/或终止延迟休克。 透皮药物递送装置和IMD包括系统状态指示器,以单独和组合地提供药物递送装置和IMD的实时操作数据。 药物输送装置还用CHF监测器来治疗CHF患者。
    • 23. 发明授权
    • Method and apparatus for reduction of pain from electric shock therapies
    • 减轻电击治疗疼痛的方法和装置
    • US06438418B1
    • 2002-08-20
    • US09568237
    • 2000-05-05
    • Charles D. SwerdlowNeal R. SwerdlowJames E. Brewer
    • Charles D. SwerdlowNeal R. SwerdlowJames E. Brewer
    • A61N1362
    • A61N1/395A61N1/36021A61N1/36071A61N1/39A61N1/3906A61N1/3956
    • A method and apparatus for pretreating a patient prior to a therapeutic painful stimulus, comprising the application of pain inhibiting stimuli to a patient prior to an application of the therapeutic painful stimulus. Applying pain inhibiting stimuli comprises the steps of sensing a need for the therapeutic painful stimulus, preparing to deliver the pain inhibiting stimuli to the patient prior to applying the therapeutic painful stimulus, and delivering the pain inhibiting stimuli to the patient prior to applying the therapeutic painful stimulus. The method and apparatus are embodied in modern, fully automatic, fully implantable, single or dual chamber atrial or ventricular cardioverter-defibrillators. The pain inhibiting prepulse method is intended primarily for use in conscious patients but may also be used in sleeping patients.
    • 一种用于在治疗性疼痛刺激之前预处理患者的方法和装置,包括在施用治疗性疼痛刺激之前向患者施用疼痛抑制刺激物。 应用疼痛抑制刺激包括以下步骤:感觉需要治疗性疼痛刺激,准备在施用治疗性疼痛刺激之前将疼痛抑制刺激递送给患者,以及在施用治疗性疼痛之前将疼痛抑制刺激递送给患者 刺激。 该方法和装置体现在现代,全自动,完全可植入,单室或双室心房或心室心律转复除颤器中。 疼痛抑制前脉冲法主要用于有意识的患者,但也可用于睡眠患者。
    • 25. 发明授权
    • Cardiac rhythm management system promoting a trial pacing
    • 心律管理系统促进心房起搏
    • US06353759B1
    • 2002-03-05
    • US09693402
    • 2000-10-20
    • Jesse W. HartleyAndrew P. KramerJeffrey E. StahmannDavid B. Krig
    • Jesse W. HartleyAndrew P. KramerJeffrey E. StahmannDavid B. Krig
    • A61N1362
    • A61N1/3621A61N1/3627A61N1/3682A61N1/395A61N1/3962A61N1/3987
    • A cardiac rhythm management system includes an atrial pacing preference (APP) filter for promoting atrial pacing. The APP filter includes an infinite impulse response (IIR) or other filter that controls the timing of delivery of atrial pacing pulses. The atrial pacing pulses are delivered at an APP-indicated pacing rate that is typically at a small amount above the intrinsic atrial heart rate. For sensed beats, the APP indicated rate is increased until it becomes slightly faster than the intrinsic atrial heart rate. The APP-indicated pacing rate is then gradually decreased to search for the underlying intrinsic atrial heart rate. Then, after a sensed atrial beat, the APP filter again increases the pacing rate until it becomes faster than the intrinsic atrial rate by a small amount. As a result, most atrial heart beats are paced, rather than sensed. This decreases the likelihood of the occurrence of an atrial tachyarrhythima, such as atrial fibrillation. The decreased likelihood of atrial tachyarrhythmia, in turn, decreases the likelihood of inducing a ventricular arrhythmia, either as a result of the atrial tachyarrhythmia, or as the result of delivering a defibrillation shock to treat the atrial tachyarrhythmia.
    • 心律管理系统包括用于促进心房起搏的心房起搏偏好(APP)滤波器。 APP滤波器包括无限脉冲响应(IIR)或其他滤波器,其控制心房起搏脉冲的递送时间。 心房起搏脉冲以APP指示的起搏速率递送,其通常在固有心房心率以上的小量起搏。 对于检测到的心跳,APP指示的速率增加,直到其变得比内在的心房心率稍快。 然后APP指示的起搏率逐渐降低,以寻找潜在的固有心房心率。 然后,在感觉到的心房搏动之后,APP滤波器再次增加起搏速率,直到其变得比固有心房率小得多。 因此,大多数心房心脏跳动起搏,而不是感觉到。 这降低了房性快速性心律失常发生的可能性,例如房颤。 房性心律失常的可能性降低反过来也降低了引起室性心律失常的可能性,由于房性快速性心律失常,或作为递送除颤休克以治疗房性快速性心律失常的结果。
    • 26. 发明授权
    • Augmentation of electrical conduction and contractility by biphasic cardiac pacing
    • 通过双相心脏起搏增强电传导和收缩
    • US06332096B1
    • 2001-12-18
    • US09504710
    • 2000-02-16
    • Morton M. Mower
    • Morton M. Mower
    • A61N1362
    • A61N1/3627A61N1/368
    • Augmentation of electrical conduction and contractility by biphasic cardiac pacing. A first stimulation phase is administered to the muscle tissue. This first stimulation phase has a predefined polarity, amplitude and duration. A second stimulation phase is then administered to the muscle tissue. This second phase also has a predefined polarity, amplitude and duration. The two phases are applied sequentially. Contrary to current thought, anodal stimulation is first applied and followed by cathodal stimulation. In this fashion, pulse conduction through the cardiac muscle is improved together with the increase in contractility. The technique can also be applied to large muscle tissue stimulation other than cardiac muscle.
    • 通过双相心脏起搏增强电传导和收缩。 向肌肉组织施用第一刺激阶段。 该第一刺激阶段具有预定义的极性,幅度和持续时间。 然后将第二刺激期施用于肌肉组织。 该第二阶段也具有预定义的极性,幅度和持续时间。 顺序应用两个阶段。 与目前的想法相反,首先应用阳极刺激,然后进行阴极刺激。 以这种方式,通过心肌的脉冲传导随着收缩性的增加而提高。 该技术也可应用于心肌以外的大肌肉组织刺激。
    • 27. 再颁专利
    • Cardiac pacemaker with hystersis behavior
    • 心脏起搏器与hystersis行为
    • USRE37454E1
    • 2001-11-27
    • US08547350
    • 1995-10-24
    • Richard SuttonIvan Bourgeois
    • Richard SuttonIvan Bourgeois
    • A61N1362
    • A61N1/365
    • A pacemaker having a hysteresis feature which permits intrinsic heart activity, controlled by the sinus node to resume optimally after pacing. The pacemaker has a programmable lower rate and upper rate, a programmable lower hysteresis rate (LRH) corresponding to a lower rate hysteresis interval (LRHI), and a programmable rate (IR) intermediate an upper pacing rate (UR) and a lower pacing rate (LR). A microprocessor measures the average rate of change MAVG in the intervals between consecutive ventricular depolarizations, and compares the last intrinsic escape interval RRN to the lower rate hysteresis interval (LRHI). If the last intrinsic escape interval RRN is longer than the lower rate hysteresis interval (LRHI), and if the value of MAVG is greater than a first preselected value SL1 but less than a second preselected value SL2, the pacemaker stimulates at the lower rate hysteresis (LRH) and thereafter gradually increases the pacing rate up to the intermediate rate (IR). A time counter maintains a continuous pacing at the intermediate rate (IR) for a predefined period of time, and the pacing rate is gradually decreased toward the lower pacing rate (LR).
    • 具有滞后特征的起搏器,其允许内部心脏活动,由起搏节点控制,以便在起搏之后恢复最佳。 起搏器具有可编程的较低速率和较高速率,对应于较低速率滞后间隔(LRHI)的可编程较低滞后速率(LRH)和中间起搏速率(UR)和较低起搏速率的可编程速率(IR) (LR)。 微处理器测量连续心室去极化之间间隔的平均变化率MAVG,并将最后的内在逃逸间隔RRN与较低速率滞后间隔(LRHI)进行比较。如果最后一个内在逃逸间隔RRN大于较低速率滞后间隔 (LRHI),并且如果MAVG的值大于第一预选值SL1但小于第二预选值SL2,起搏器以较低的速率滞后(LRH)刺激,然后逐渐增加起搏速率直到中间速率 (IR)。 时间计数器以预定的时间段维持中间速率(IR)的连续起搏,并且起搏速率朝向较低的起搏速率(LR)逐渐降低。